share_log

Jefferies Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $8

Jefferies Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $8

杰富瑞集团以买入评级启动对ImmunityBio的报道,宣布目标股价为8美元
Benzinga Real-time News ·  2022/08/03 07:18

Jefferies analyst Kelly Shi initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $8.

杰富瑞分析师凯利·施以买入评级开始报道ImmunityBio(纳斯达克股票代码:IBRX),并宣布目标股价为8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发